Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2016-06-30
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery
NCT02919345
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
NCT03248401
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
NCT02983214
Study of the Vascular Effects of Serelaxin
NCT01979614
Effects of a Dietary Supplement Composed of Diosmin, Hesperidin, Bromelain, and Ruscus Aculeatus on the Quality of Life in Subjects With Lower Limb Disorders Possibly Prodromal to Chronic Venous Disease
NCT07185386
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
Women will use Cimifuga Racemosa for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
Cimifuga Racemosa
Experimental group will use 160mg of Cimifuga Racemosa for 28 days
Placebo
Women will use Placebo for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
Placebo
patients of the placebo group will use placebo once a day for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cimifuga Racemosa
Experimental group will use 160mg of Cimifuga Racemosa for 28 days
Placebo
patients of the placebo group will use placebo once a day for 28 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women without menstrual cycles within the last 12 months and follicle stimulating hormone (FSH) \> 30 International Units(IU)/Litre
* Women that were not using drugs with potential vascular effect within the last 1 year
* Women that were not using hormone replacement therapy within the last 1 year
Exclusion Criteria
* Blood Pressure \> 160/90 mm Hg.
* Breast and or endometrial cancer
* History of acute myocardial infarction
* Diabetes
* Vaginal bleeding of any origin
* Hepatic disease
* Thrombophlebitis or thromboembolic disorders
45 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federal University of Minas Gerais
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Selmo Geber
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Selmo Geber, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Universidde Federal de Minas Gerais
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital das Clinicas - Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ETIC - CR-0417.0.203.000-09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.